Stock Price & Analysis

Based on the provided data and recent market developments, here's a concise analysis of REGN stock:

Technical Analysis

The stock is currently trading at $688.01 in pre-market with a +0.94% change. Technical indicators show an RSI(14) of 36.28, suggesting oversold conditions. The Fibonacci pivot points indicate immediate resistance at $735.31 and support at $676.46.

Recent Business Updates Regeneron reported preliminary Q4 results with Eylea and Eylea HD combined sales of $1.5 billion in the US. Eylea HD's standalone sales were $305 million, while regular Eylea sales were $1.19 billion. The company has several upcoming catalysts:

• FDA review for Eylea HD's longer-term data (target date: April 20, 2025)
• Planned sBLA submission for Eylea HD's four-week dosing in Q1 2025
• Dupixent label expansion review for chronic urticaria (target date: April 18, 2025)

Analyst Sentiment Recent analyst actions show mixed views:

• UBS downgraded to Hold with $738 target, citing concerns about Eylea revenue trajectory
• Citigroup lowered target to $795 but maintained Hold rating
• Wells Fargo maintains Buy rating with $900 target

Recommendation Based on the oversold technical conditions, multiple near-term catalysts, and strong product portfolio including $1 billion+ Libtayo sales, REGN appears attractive at current levels. However, investors should be mindful of ongoing concerns about Eylea franchise competition and adoption rates.

Based on the provided data and recent market updates, here's the price prediction for REGN stock in 2025:

Regeneron's stock (REGN) is projected to reach $735-755 by mid-2025, driven by strong Eylea franchise performance and expanding pipeline. The company's Q4 2024 combined Eylea/Eylea HD sales of $1.5 billion demonstrates market leadership despite competition. Additional upside potential exists with pending FDA approvals for Dupixent's label expansion (April 18, 2025) and Eylea HD's longer-term data review (April 20, 2025).

The stock currently trades at $688.01 as of January 21, 2025, with technical indicators showing RSI at 36.28 suggesting oversold conditions that could lead to a potential rebound.

The S1 support level for REGN Stock is $672.02 ,The R1 resistant level for REGN Stock is $716.7.

As of the end of day on 2025-01-24, the price of REGN Stock was $675.

The target price for REGN Stock according to analyst rating is 1,053, with the highest price target at 1,300 and the lowest at 565.00. Analysts have a Moderate Buy rating on REGN Stock overall.

The market cap of REGN is $74.3B.

Based on the provided data and recent market updates, here's a concise analysis of REGN's valuation:

Valuation Analysis REGN currently trades at a PE of 26x, which is relatively reasonable compared to its historical average and biotech sector peers. The EV/EBITDA ratio of 23.3x suggests moderate premium valuation.

Recent Performance The stock is currently trading at $688.01, showing significant decline from its recent highs. The RSI of 36.28 indicates the stock is approaching oversold territory but hasn't reached extreme levels yet.

Key Concerns UBS recently downgraded REGN to Hold from Strong Buy with a significantly reduced price target of $738 from $1,130, citing concerns about Eylea revenues and limited high-dose adoption rates. The disconnect between market's short-term focus on Eylea revenues versus Regeneron's long-term business strategy raises valuation concerns.

Growth Outlook Despite near-term Eylea challenges, the company maintains strong pipeline development across immunology, inflammation, oncology and genetic medicines. Libtayo exceeded $1 billion in sales for 2024, demonstrating portfolio diversification success.

Conclusion At current levels, REGN appears fairly valued considering the near-term Eylea headwinds balanced against its robust pipeline and diversification efforts. The stock's current trading price reflects appropriate market concerns while maintaining reasonable valuation metrics relative to growth prospects.

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases. It helps in accelerating and improving the traditional drug development process through its VelociSuite technologies. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; REGEN-COV; Kevzara (sarilumab) Injection, and others. The Company’s solid tumor and other oncology and autoimmune cell therapy programs include the bbT369 program in B-NHL, SC-DARIC33 in AML, MUC16 in ovarian cancer, MAGE-A4, autoimmune, and several unnamed targets.

Based on the provided data and recent developments, here's a price prediction analysis for REGN stock by 2030:

Regeneron's stock is projected to reach approximately $1,250-1,300 by 2030, driven by strong performance in its core products like Eylea/Eylea HD ($6 billion in 2024 US sales) and expansion of Dupixent into new indications. The company's robust pipeline with 40 drugs in development representing billions in potential sales, along with strategic collaborations like the recent $119.5M investment in Truveta for advancing data-driven discovery, positions it well for sustained growth. The company's consistent focus on innovation and R&D investment, coupled with its expanding commercial portfolio including blockbuster medicines targeting a market opportunity exceeding $220B by 2030, supports this bullish long-term outlook.

REGN has a total of 13450 employees.